🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Prakash Ambady

ORCID: 0000-0003-4812-0581

Also affiliated with Providence Portland Medical Center, Providence Center, Providence Health & Services

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.896Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Safety of intra-arterial chemotherapy with or without osmotic blood–brain barrier disruption for the treatment of patients with brain tumors

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac104

Top 23%

0.896DataRank

Top 23%24 citations

Prakash Ambady, Matthew K. McIntyre, John Philip Tabb, Cymon Kersch, Caleb Nerison +11 more

Papers

Driven by 13 papers — median percentile 77. Top paper: “Safety of intra-arterial chemotherapy with or without osmotic blood–brain barrier disruption for the treatment of patients with brain tumors”.

Safety of intra-arterial chemotherapy with or without osmotic blood–brain barrier disruption for the treatment of patients with brain tumors

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac104

Top 23%

0.896DataRank

Top 23%24 citations

Prakash Ambady, Matthew K. McIntyre, John Philip Tabb, Cymon Kersch, Caleb Nerison +11 more

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)

Neuro-Oncology(2021)10.1093/neuonc/noab020

N/A

0.773DataRank · unranked

172 citations

Letterio S. Politi, Nicoletta Anzalone, Heiko Schöder, Christopher P. Fox, Jerrold L. Boxerman +16 more

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma

Epilepsy & Behavior Reports(2022)10.1016/j.ebr.2022.100526

N/A

0.529DataRank · unranked

33 citations

Prakash Ambady, David Spencer, Anh Huan Vo

[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab

Neuro-Oncology Practice(2022)10.1093/nop/npac021

N/A

0.360DataRank · unranked

10 citations

Prakash Ambady, Jeanne Link, Kenneth A. Krohn, Ahmed M. Raslan, Nadine Mallak +4 more

Osmotic blood-brain barrier disruption with mannitol followed by methotrexate, rituximab, and carboplatin in treating patients with newly diagnosed primary central nervous system lymphoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2077

N/A

0.122DataRank · unranked

1 citations

Nancy D. Doolittle, Edward A. Neuwelt, Rongwei Fu, Gerda Teglassy, Anh Huan Vo +1 more

Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa093

N/A

0DataRank · unranked

7 citations

Cheryl Claunch, Prakash Ambady, Elmar Bucher, Daniel L. Schwartz, Ramon Barajas +8 more

Long-Term Outcomes of Intra-Arterial Chemotherapy for Progressive or Unresectable Pilocytic Astrocytomas: Case Studies

Neurosurgery(2020)10.1093/neuros/nyaa588

N/A

0DataRank · unranked

12 citations

Dominic A. Siler, Ricardo López, Csanád Várallyay, João Prola Netto, Jenny Firkins +5 more

Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac027

N/A

0DataRank · unranked

14 citations

László Szidonya, Ramon Barajas, Prakash Ambady, Csanád Várallyay, Edward A. Neuwelt +1 more

Deciphering spatially distinct immune microenvironments in glioblastoma using ferumoxytol and gadolinium-enhanced and FLAIR hyperintense MRI phenotypes

Neuro-Oncology Advances(2023)10.1093/noajnl/vdad148

N/A

0DataRank · unranked

5 citations

Cymon Kersch, Leslie L. Muldoon, Prakash Ambady, Christina A. Harrington, Rongwei Fu +5 more

Comparison of dynamic susceptibility contrast (DSC) using gadolinium and iron-based contrast agents in high-grade glioma at high-field MRI

The Neuroradiology Journal(2024)10.1177/19714009241242596

N/A

0DataRank · unranked

4 citations

Daniel L. Schwartz, Xin Li, Leslie L. Muldoon, Jared Stoller, Cooper Stateler +9 more

Clinical Utility of [ 18 F]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma

American Journal of Neuroradiology(2025)10.3174/ajnr.a9120

N/A

0DataRank · unranked

1 citations

Kellen Vo Vu, Rongwei Fu, Andrew Brandmaier, László Szidonya, Gagandeep Choudhary +41 more

Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts

Cancer Gene Therapy(2021)10.1038/s41417-021-00324-6

N/A

0DataRank · unranked

10 citations

Yingjen Jeffrey Wu, Cymon Kersch, Joshua M. Walker, Samantha Holland, Leslie L. Muldoon +2 more

Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma

American Journal of Neuroradiology(2020)10.3174/ajnr.a6600

N/A

0DataRank · unranked

15 citations

Daniel L. Schwartz, Heather McConnell, Cymon Kersch, Xin Li, Bronwyn E. Hamilton +20 more